Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
This real-world evidence study supports the non-inferiority of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in terms of efficacy and safety in patients with resectable NSCLC. We believe that our findings could be an important reference for future studies comparing pembrolizumab- and tislelizumab-based treatment combinations in the neoadjuvant setting.
Authors
- Jinyou Liu
- Siying Ren (ORCID: https://orcid.org/0000-0001-6618-690X)
- Chao Zeng (ORCID: https://orcid.org/0000-0002-6130-2438)
- Lulu Yang (ORCID: https://orcid.org/0000-0002-3979-2522)
- Yan Hu (ORCID: https://orcid.org/0000-0001-6506-0694)
- Wenliang Liu (ORCID: https://orcid.org/0000-0003-4202-8637)
- Fang Wu (ORCID: https://orcid.org/0000-0002-3177-1727)
- Juan Feng
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tlcr-24-721
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56